Proteomic analysis of RCL2 paraffin-embedded tissues

por Bellet, V, Boissière, F, Bibeau, F, Desmetz, C, Berthe, M L, Rochaix, P, Maudelonde, T, Mangè, A, Solassol, J
Publicado 2008

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

por Oden-Gangloff, A, Di Fiore, F, Bibeau, F, Lamy, A, Bougeard, G, Charbonnier, F, Blanchard, F, Tougeron, D, Ychou, M, Boissière, F, Le Pessot, F, Sabourin, J-C, Tuech, J-J, Michel, P, Frebourg, T
Publicado 2009

Antibody targeting of claudin-1 as a potential colorectal cancer therapy

por Cherradi, S., Ayrolles-Torro, A., Vezzo-Vié, N., Gueguinou, N., Denis, V., Combes, E., Boissière, F., Busson, M., Canterel-Thouennon, L., Mollevi, C., Pugnière, M., Bibeau, F., Ychou, M., Martineau, P., Gongora, C., Del Rio, M.
Publicado 2017

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

por Samalin, E, Bouché, O, Thézenas, S, Francois, E, Adenis, A, Bennouna, J, Taieb, J, Desseigne, F, Seitz, J F, Conroy, T, Galais, M P, Assenat, E, Crapez, E, Poujol, S, Bibeau, F, Boissière, F, Laurent-Puig, P, Ychou, M, Mazard, T
Publicado 2014